Survivors of single agent anti-PD-1 and combined anti CX3CR1 + anti-PD-1 had 100% percent survival when re-challenged with CT26 while control mice succumbed to the tumor, confirming immunological memory after the antibody treatments (Figure 2E). Here, CX3CR1 is linked to neoplasm.